JP2018518527A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518527A5
JP2018518527A5 JP2017567429A JP2017567429A JP2018518527A5 JP 2018518527 A5 JP2018518527 A5 JP 2018518527A5 JP 2017567429 A JP2017567429 A JP 2017567429A JP 2017567429 A JP2017567429 A JP 2017567429A JP 2018518527 A5 JP2018518527 A5 JP 2018518527A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
allogeneic
cell population
human patient
cmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017567429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518527A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/038530 external-priority patent/WO2016209816A1/en
Publication of JP2018518527A publication Critical patent/JP2018518527A/ja
Publication of JP2018518527A5 publication Critical patent/JP2018518527A5/ja
Pending legal-status Critical Current

Links

JP2017567429A 2015-06-26 2016-06-21 T細胞療法によるcmv網膜炎の治療方法 Pending JP2018518527A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562185558P 2015-06-26 2015-06-26
US62/185,558 2015-06-26
US201562191304P 2015-07-10 2015-07-10
US62/191,304 2015-07-10
PCT/US2016/038530 WO2016209816A1 (en) 2015-06-26 2016-06-21 Methods of treating cmv retinitis by t cell therapy

Publications (2)

Publication Number Publication Date
JP2018518527A JP2018518527A (ja) 2018-07-12
JP2018518527A5 true JP2018518527A5 (OSRAM) 2019-08-08

Family

ID=56404300

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017567429A Pending JP2018518527A (ja) 2015-06-26 2016-06-21 T細胞療法によるcmv網膜炎の治療方法

Country Status (6)

Country Link
US (2) US10342864B2 (OSRAM)
EP (2) EP3313419B1 (OSRAM)
JP (1) JP2018518527A (OSRAM)
CN (1) CN107921065A (OSRAM)
HK (1) HK1254397A1 (OSRAM)
WO (1) WO2016209816A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120059581A (ko) 2009-08-24 2012-06-08 윌슨 울프 매뉴팩처링 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ctl주의 생성
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
IL298359B2 (en) 2015-09-18 2025-12-01 Baylor College Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
KR102815003B1 (ko) * 2019-05-28 2025-05-30 도요보 가부시키가이샤 폴리에스테르 필름, 적층 필름 및 그 용도
CA3149145A1 (en) * 2019-07-29 2021-02-04 Baylor College Of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
RU2740943C1 (ru) * 2020-03-23 2021-01-21 Борис Сергеевич Першин Способ лечения цитомегаловирусного ретинита после трансплантации гемопоэтических стволовых клеток

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
DE69718029T2 (de) * 1996-10-11 2003-10-16 The Regents Of The University Of California, Oakland Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6156317A (en) 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
JP2003501076A (ja) 1999-06-04 2003-01-14 フロリアン・ケルン ヒトcmvに対するワクチン接種のためのペプチド
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
JP4099058B2 (ja) 2000-10-20 2008-06-11 シティ・オブ・ホープ ヒトサイトメガロウィルスpp150の免疫反応性ペプチドctlエピトープ
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20030139466A1 (en) * 2001-11-29 2003-07-24 Peritt David L. Methods for pretreating a subject with extracorporeal photopheresis
CN1659436A (zh) 2002-02-28 2005-08-24 英特塞尔股份公司 分离配体的方法
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
DK3156069T3 (da) 2008-06-20 2020-09-21 Univ Duke Sammensætninger, fremgangsmåder, og kits til fremkaldelse af et immunrespons
EP2370593B1 (en) 2008-11-28 2016-03-30 Emory University Methods for determining the efficacy of pd-1 antagonists
KR20120059581A (ko) 2009-08-24 2012-06-08 윌슨 울프 매뉴팩처링 다중 종양 항원 또는 다중 바이러스에 대해 특이성을 갖는 ctl주의 생성
GB0917094D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
EP2770834A4 (en) * 2011-10-26 2015-11-25 Chimerix Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Similar Documents

Publication Publication Date Title
Zheng et al. Hepatitis B functional cure and immune response
Saez-Cirion et al. Immunometabolism and HIV-1 pathogenesis: food for thought
Archin et al. Eradicating HIV-1 infection: seeking to clear a persistent pathogen
Gattinoni et al. T memory stem cells in health and disease
Liu et al. HIV-1 functional cure: will the dream come true?
Luo et al. B cell response to vaccination
Hütter Stem cell transplantation in strategies for curing HIV/AIDS
Ng et al. IL-10: achieving balance during persistent viral infection
JP2017515901A5 (OSRAM)
Pannetier et al. Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus
Kamphorst et al. Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity
JP2018524335A (ja) Hiv予備免疫化および免疫療法
Ahluwalia et al. Infection and immune memory: variables in robust protection by vaccines against SARS-CoV-2
JP2019512020A5 (OSRAM)
JP2018520095A5 (OSRAM)
Ravens et al. Human γδ T cell receptor repertoires in peripheral blood remain stable despite clearance of persistent hepatitis C virus infection by direct-acting antiviral drug therapy
Wang et al. Tissue-resident memory-like ILCs: innate counterparts of TRM cells
JP2014512391A5 (OSRAM)
JP2012532624A5 (OSRAM)
Hemann et al. Plasmacytoid dendritic cells require direct infection to sustain the pulmonary influenza A virus-specific CD8 T cell response
Kavazović et al. Cheating the hunger games; mechanisms controlling clonal diversity of CD8 effector and memory populations
Martin et al. Influence of time and number of antigen encounters on memory CD8 T cell development
Conway et al. Cellular therapies for the treatment and prevention of SARS-CoV-2 infection
Kotton et al. Slaying the “Troll of Transplantation”—new frontiers in cytomegalovirus management: A report from the CMV International Symposium 2023
Grant-Klein et al. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses